Mini Review ARTICLE
The treatment of giant cell arteritis in different clinical settings
- 1Friedrich-Schiller-Universität Jena, Germany
- 2Chugai Pharmaceutical Co., Ltd, Japan
This paper aims to raise awareness of the different disease courses, comorbidities, and therapy situations in patients with giant cell arteritis (GCA), which require a differentiated approach and often a deviation from current treatment guidelines. With the approval of tocilizumab (TOC), which specifically binds to both soluble and membrane-bound IL-6 receptor and inhibits IL-6 receptor-mediated signalling, the spectrum of available effective treatment options has been significantly broadened. TOC yields an extensive range of possible applications that go beyond a glucocorticoid-saving effect. In this context, the treatment of GCA is dependent on the disease course as well as the associated comorbidities. The different stages of GCA in association to co-morbidities require an detailed treatment strategy.
Keywords: Giant cell (temporal) arteritis, Tocilizumab (TCZ), glucococorticoids, Treatment, comorbidiity
Received: 23 Oct 2018;
Accepted: 18 Dec 2018.
Edited by:Philippe Saas, INSERM U1098 Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, France
Reviewed by:Bernard Bonnotte, Université de Bourgogne, France
Juan C. Amor-Dorado, Hospital Can Misses, Spain
Copyright: © 2018 Pfeil, Oelzner and Hellmann. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Alexander Pfeil, Friedrich-Schiller-Universität Jena, Jena, 07737, Thuringia, Germany, email@example.com